Innate Pharma (IPHA)
(Delayed Data from NSDQ)
$2.16 USD
+0.01 (0.47%)
Updated Jul 22, 2024 03:59 PM ET
After-Market: $2.25 +0.09 (4.17%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IPHA 2.16 +0.01(0.47%)
Will IPHA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IPHA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IPHA
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
IPHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis
Other News for IPHA
Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024
Innate falls on updated phase 1/2 data on blood cancer asset teamed with Sanofi
Innate Pharma announces updated results from SAR443579/IPH6101
Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
Analysts Are Bullish on Top Healthcare Stocks: Accuray (ARAY), Innate Pharma (IPHA)